Astellas will make an upfront payment of $20m to 4DMT. Credit: JHVEPhoto via Shutterstock.com.

Astellas Pharma has entered an agreement for licensing 4D Molecular Therapeutics’ (4DMT) R100 vector for a genetic target associated with rare monogenic ophthalmic ailments.

Retinotropic R100 is an adeno-associated virus (AAV) vector intended to be administered intravitreally.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Astellas holds options to include up to two further targets linked to rare monogenic ophthalmic ailments, contingent on the payment of further option exercise fees.

R100 has the potential to cross the internal limiting membrane barrier and successfully transduce the whole retina. This approach leads to transgene expression in retinal cells. 

All three clinical-stage ophthalmic products of 4DMT leverage the R100 vector. 

See Also:

Astellas will make an upfront payment of $20m to 4DMT. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

4DMT is eligible to receive option fees and milestone payments totalling $942.5m.

This payment includes $15m near-term development milestone fees for the first target. 

Astellas will also make royalty payments to 4DMT on net sales of products that are licensed under the agreement.

Research, development, production and marketing will be carried out by Astellas following licensing.

4DMT co-founder and CEO David Kirn stated: “With over 70 patients dosed to date with R100-based product candidates in wet age-related macular degeneration and rare ophthalmic diseases, this collaboration also demonstrates the modularity of the therapeutic vector evolution platform resulting in the efficient design and development of new intravitreal products.”

The latest development comes after the US Food and Drug Administration granted priority review for Astellas’ biologics licence application for zolbetuximab for gastric cancer.